Vistusertib (dual m-TORC1/2 inhibitor) in combination with paclitaxel in patients with high-grade serous ovarian and squamous non-small-cell lung cancer
暂无分享,去创建一个
N. Tunariu | W. Brugger | D. Talbot | U. Banerji | J. Spicer | E. Harrington | R. Ruddle | F. Raynaud | E. Hall | M. Brada | S. Banerjee | J. D. de Bono | R. Jones | S. Carreira | K. Swales | R. Sundar | N. Steele | B. Basu | J. Evans | H. Tovey | J. Dawes | R. H. Wilson | M. Parmar | A. Turner | A. I. Ingles Garces | M. Krebs | A. Ingles Garces | F. M. de Oliveira | B. Purchase | Susana Banerjee | Bristi Basu | Michael Brada | Joanna C. Dawes | Matthew G Krebs | Raghav Sundar | Richard Wilson | James Spicer | Robert H. Jones | Denis Talbot | A. H. I. Garces | Wolfram Brugger | Elizabeth A. Harrington | Emma Hall | F. D. Oliveira | Florence I. Raynaud | Beth Purchase | J. D. Bono
[1] E. Karteris,et al. Kinase Inhibitors and Ovarian Cancer , 2019, Cancers.
[2] H. Hua,et al. Targeting mTOR for cancer therapy , 2019, Journal of Hematology & Oncology.
[3] M. Leach,et al. Evaluation of the combination of the dual m-TORC1/2 inhibitor vistusertib (AZD2014) and paclitaxel in ovarian cancer models , 2017, Oncotarget.
[4] M. Frisinghelli,et al. Weekly paclitaxel after first-line failure in patients with advanced non-small-cell lung cancer: everyday clinical practice in a single centre , 2017, Anti-cancer drugs.
[5] Suzanne F. Jones,et al. TAK-228 (formerly MLN0128), an investigational dual TORC1/2 inhibitor plus paclitaxel, with/without trastuzumab, in patients with advanced solid malignancies , 2017, Cancer Chemotherapy and Pharmacology.
[6] H. Gabra,et al. OCTOPUS: A randomised, multi-centre phase II umbrella trial of weekly paclitaxel+/- novel agents in platinum-resistant ovarian cancer—Vistusertib (AZD2014). , 2017 .
[7] Y. Shentu,et al. Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. , 2016, The New England journal of medicine.
[8] Paul Workman,et al. Critical parameters in targeted drug development: the pharmacological audit trail. , 2016, Seminars in oncology.
[9] Michael T. Frow,et al. Characterisation of the Phosphatidylinositol 3-Kinase Pathway in Non-Small Cell Lung Cancer Cells Isolated from Pleural Effusions , 2016, Oncology.
[10] L. Crinò,et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. , 2015, The New England journal of medicine.
[11] M. Ranson,et al. First-in-Human Pharmacokinetic and Pharmacodynamic Study of the Dual m-TORC 1/2 Inhibitor AZD2014 , 2015, Clinical Cancer Research.
[12] U. Banerji,et al. Higher Risk of Infections with PI3K–AKT–mTOR Pathway Inhibitors in Patients with Advanced Solid Tumors on Phase I Clinical Trials , 2015, Clinical Cancer Research.
[13] U. Banerji,et al. First-in-Human Study of CH5132799, an Oral Class I PI3K Inhibitor, Studying Toxicity, Pharmacokinetics, and Pharmacodynamics, in Patients with Metastatic Cancer , 2014, Clinical Cancer Research.
[14] A. Reuss,et al. Bevacizumab combined with chemotherapy for platinum-resistant recurrent ovarian cancer: The AURELIA open-label randomized phase III trial. , 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] Linette Ruston,et al. Optimization of potent and selective dual mTORC1 and mTORC2 inhibitors: the discovery of AZD8055 and AZD2014. , 2013, Bioorganic & medicinal chemistry letters.
[16] Steven J. M. Jones,et al. Comprehensive genomic characterization of squamous cell lung cancers , 2012, Nature.
[17] Jianping Shi,et al. A meta-analysis of paclitaxel-based chemotherapies administered once every week compared with once every 3 weeks first-line treatment of advanced non-small-cell lung cancer. , 2012, Lung cancer.
[18] M. Gore,et al. The Association of PI3 Kinase Signaling and Chemoresistance in Advanced Ovarian Cancer , 2012, Molecular Cancer Therapeutics.
[19] Y. Ohe,et al. Risk Factors for Treatment-Related Death Associated with Chemotherapy and Thoracic Radiotherapy for Lung Cancer , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.
[20] Benjamin J. Raphael,et al. Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.
[21] F. André,et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[22] S. Kaye,et al. Weekly paclitaxel in the treatment of recurrent ovarian cancer , 2010, Nature Reviews Clinical Oncology.
[23] F. Rojo,et al. Phase Ib study of weekly mammalian target of rapamycin inhibitor ridaforolimus (AP23573; MK-8669) with weekly paclitaxel. , 2010, Annals of oncology : official journal of the European Society for Medical Oncology.
[24] Suzanne F. Jones,et al. Dose- and schedule-dependent inhibition of the mammalian target of rapamycin pathway with everolimus: a phase I tumor pharmacodynamic study in patients with advanced solid tumors. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.